Market Overview

Aegis Capital Reiterates Buy Rating on BioSpecifics Technologies Ahead of Conference Call

Related BSTC
18 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Expectations

In a report published Monday, Aegis Capital reiterated its Buy rating and $50.00 price target on BioSpecifics Technologies Corp. (NASDAQ: BSTC).

Aegis Capital noted, “We are revising our numbers ahead of BioSpecifics' earnings conference call this week to account for the fact that, unlike its partner Auxilium Pharmaceuticals, BioSpecifics is not recognizing additional revenue in 4Q 2012 as a result of Pfizer's termination of its licensing agreement with Auxilium on Xiaflex in Europe. Regardless, we continue to believe that investors should take note of BioSpecifics' low valuation and risk-mitigated status at this juncture. From our perspective, the firm could have a catalyst-rich 2013. In particular, we expect proof-of-concept data in human and canine lipoma clinical trials with Xiaflex in the summer.”

BioSpecifics Technologies Corp. closed on Friday at $16.29.

Latest Ratings for BSTC

Mar 2016Rodman & RenshawInitiates Coverage onBuy
Nov 2014MKM PartnersMaintainsBuy
Aug 2014MKM PartnersMaintainsBuy

View More Analyst Ratings for BSTC
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Reiteration Analyst Ratings


Related Articles (BSTC)

View Comments and Join the Discussion!